Teva : Reinitiation of coverage with a Buy recommendation, reduced uncertainty on opioid litigation
Teva released reassuring results in Q2 2022 at the end of July with a return to positive revenue growth on constant currency and the confirmation of most of its full-year targets. The revenue objective was cut owing to the appreciation of the US dollar whilst the guidance for EBITDA ($ 4.7-5.0bn) and FCF ($ 1.9-2.2bn) is intact. - The Q2 results publication was also marked by the unveiling of (1) the company’s long-term targets and (2) an in-principle nationwide agreement in the U...Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.